Powered by

Batavia Biosciences to deploy Horizon Discovery's CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologics

Sep 03, 2019 - Thomson Reuters ONE

Leiden, 3 September 2019 - Today, Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery's GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC) and IDBiologics, a company which focuses on developing human antibo...